Search Results: Treatment + BRCA + Breast Cancer + Stage 4 (12 results)
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only.
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)
https://www.facingourrisk.org/research-clinical-trials/study/179/targeted-therapy-rp-3500-alone-or-in-combination-with-talazoparib-or-gemcitabine-in-advanced-solid-tumors-with-dna-damage-repair-mutations-tresr-study
Treatment
Advanced solid tumors
This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
https://www.facingourrisk.org/research-clinical-trials/study/155/atr-inhibitor-plus-niraparib-study-in-advanced-solid-tumors-and-ovarian-cancer
Treatment
Advanced ovarian cancer or other solid tumors
This study will look at how well how well people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib.
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/178/a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations
https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations
Treatment
Advanced solid tumors
This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.
HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/147/olaparib-palbociclib-and-fulvestrant-for-brca-associated-erpr-positive-her2-negative-metastatic-breast-cancer
Treatment
The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Treatment
This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for germline BRCA1/2 carriers) is effective in this population.
Additional Results on Clinicaltrials.gov Treatment + BRCA + Breast Cancer + Stage 4
10 results
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
NCT ID: NCT05807126 (https://classic.clinicaltrials.gov/show/NCT05807126)
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://classic.clinicaltrials.gov/show/NCT03990896)
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
NCT ID: NCT03685331 (https://classic.clinicaltrials.gov/show/NCT03685331)
Olaparib In Metastatic Breast Cancer
NCT ID: NCT03344965 (https://classic.clinicaltrials.gov/show/NCT03344965)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://classic.clinicaltrials.gov/show/NCT03428802)
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://classic.clinicaltrials.gov/show/NCT04150042)
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://classic.clinicaltrials.gov/show/NCT04090567)
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
NCT ID: NCT04991480 (https://classic.clinicaltrials.gov/show/NCT04991480)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05252390 (https://classic.clinicaltrials.gov/show/NCT05252390)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://classic.clinicaltrials.gov/show/NCT05417594)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.